|
Real-world treatment patterns among patients (pts) diagnosed with primary mediastinal large B-cell lymphoma (PMBCL) in the United States (US). |
|
|
|
|
|
Research Funding - Merck (Inst) |
|
|
Research Funding - Merck (Inst) |
|
|
|
Stock and Other Ownership Interests - Johnson & Johnson; Merck |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
Research Funding - Merck (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Adaptive Biotechnologies; Affimed Therapeutics; Bristol-Myers Squibb; Merck; Pfizer |
Research Funding - Adaptive Biotechnologies (Inst); Affimed Therapeutics (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Otsuka (Inst); Roche/Genentech (Inst); Sigma-Tau (Inst); Tensha Therapeutics (Inst) |
Travel, Accommodations, Expenses - Genmab |